In contrast, 57% (4/7) and 66% (4/6) of the IFN-β-treated MS patients with active disease had a detectable CD8+ T cell response to EBV (Figure 1 B) and CMV (data not shown), respectively. The gene discussed is IFNB1; the disease is myeloid sarcoma.